Promising Clinical Data and Serotonergic Modulation Reinforce Buy Rating for Bright Minds and Harmony

H.C. Wainwright analyst has reiterated their bullish stance on AES stock, giving a Buy rating on December 5.

H.C. Wainwright’s rating is based on the promising clinical data presented at the American Epilepsy Society 2025 Annual Meeting, which bolsters the confidence in the serotonergic modulation approach for treating developmental and epileptic encephalopathies (DEEs). The updated data for bexicaserin demonstrated sustained seizure reduction over two years, reinforcing its efficacy across various syndromes such as Dravet syndrome and Lennox-Gastaut syndrome.
The initial Phase 3 open-label extension data from the ARGUS trial showed significant seizure reduction in patients treated with EPX-100, with favorable tolerability and long-term retention. These results strengthen the clinical foundation for 5-HT2C receptor modulation and suggest that serotonergic drugs can effectively recalibrate network imbalances in DEEs. The data supports the potential of Bright Minds’ BMB-101 and Harmony’s EPX-100, leading to a reiterated Buy rating and increased price targets for these companies.